Key Points BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer. However, it's too early to write off BioNTech's chances. 10 stocks we like better than BioNTech Se › BioNTech 's (NASDAQ: BNTX) shares were flying high in the aftermath of Moderna 's (NASDAQ: MRNA) and Merck 's (NYSE: MRK) announcement of impressive late-stage results for personalized messenger RNA (mRNA) cancer vaccine intismeran autogene in combination with Keytruda. The surge made sense, considering that BioNTech is developing its own mRNA cancer vaccines. However, BioNTech's momentum came to a screeching halt with the company's update on Aug.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.